SC
MEDP icon

Scholtz & Company’s Medpace MEDP Stock Holding History

Scholtz & Company’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,466
Closed -$489K – 55
2024
Q3 		$489K Sell
1,466
-205
-12% -$77.9K 0.23% 40
2024
Q2 		$688K Buy
1,671
+71
+4% +$28.1K 0.29% 37
2024
Q1 		$647K Buy
+1,600
New +$563K 0.29% 36

Other funds holding MEDP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Scholtz & Company's MEDP Position: Q4 2024 in Review

Scholtz & Company sold out of Medpace (MEDP) in Q4 2024, closing a stake of 1,466 shares — an estimated $489K sold.

Scholtz & Company first reported a position in MEDP in Q1 2024 and held it in 3 quarters. The position peaked at $688K in Q2 2024. 592 funds tracked by Wall St. Rank hold MEDP as of Q4 2024.

  • Scholtz & Company reported no remaining Medpace position as of Q4 2024 after selling out during the quarter.
  • Scholtz & Company sold 1,466 Medpace shares in Q4 2024, an estimated $489K.
  • Scholtz & Company first reported a position in Medpace in Q1 2024 and held it in 3 quarters.
  • Scholtz & Company's Medpace position peaked at $688K in Q2 2024.
  • 592 funds tracked by Wall St. Rank held Medpace as of Q4 2024.

Based on Scholtz & Company's 13F filing for Q4 2024, filed 12 Feb 2025.